A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Abstract: Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refract...
Furkejuvvon:
| Váldodahkkit: | , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Elsevier
2018-04-01
|
| Ráidu: | Blood Advances |
| Liŋkkat: | http://www.sciencedirect.com/science/article/pii/S2473952920310442 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|